[go: up one dir, main page]

CY1106091T1 - Εμβολιο εναντι hbv και hpv - Google Patents

Εμβολιο εναντι hbv και hpv

Info

Publication number
CY1106091T1
CY1106091T1 CY20061100714T CY061100714T CY1106091T1 CY 1106091 T1 CY1106091 T1 CY 1106091T1 CY 20061100714 T CY20061100714 T CY 20061100714T CY 061100714 T CY061100714 T CY 061100714T CY 1106091 T1 CY1106091 T1 CY 1106091T1
Authority
CY
Cyprus
Prior art keywords
antigen
hpv
vaccine against
hepatitis
virus
Prior art date
Application number
CY20061100714T
Other languages
English (en)
Inventor
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1106091T1 publication Critical patent/CY1106091T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Παρέχονται νέες συνθέσεις συνδυασμένου εμβολίου που περιλαμβάνουν ιϊκό αντιγόνο ηπατίτιδας Β και ένα HPV αντιγόνο και προαιρετικά επιπλέον ένα ή περισσότερα των ακολούθων : ένα EBV αντιγόνο, αντιγόνο ηπατίτιδας Α ή απενεργοποιημένο εξασθενημένο ιό, ιϊκό αντιγόνου απλού έρπη, VZV αντιγόνο, HCMV αντιγόνο, αντιγόνο Toxoplasma gondii. Οι συνθέσεις εμβολίου συνταγοποιούνται με ένα βοηθητικό, το οποίο είναι ένας κατά προτίμηση διεγέρτης της απόκρισης ΤΗ1 κυττάρου, όπως 3D-MPL και QS21.
CY20061100714T 1999-09-07 2006-06-05 Εμβολιο εναντι hbv και hpv CY1106091T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921147.6A GB9921147D0 (en) 1999-09-07 1999-09-07 Novel composition
PCT/EP2000/008728 WO2001017550A2 (en) 1999-09-07 2000-09-06 Vaccine against hbv and hpv

Publications (1)

Publication Number Publication Date
CY1106091T1 true CY1106091T1 (el) 2011-06-08

Family

ID=10860521

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100714T CY1106091T1 (el) 1999-09-07 2006-06-05 Εμβολιο εναντι hbv και hpv

Country Status (29)

Country Link
US (2) US7371390B2 (el)
EP (2) EP1731167B1 (el)
JP (1) JP4694745B2 (el)
KR (1) KR100782637B1 (el)
CN (1) CN1171637C (el)
AR (1) AR025503A1 (el)
AT (2) ATE323509T1 (el)
AU (1) AU765245B2 (el)
BR (1) BR0014172A (el)
CA (1) CA2381047C (el)
CY (1) CY1106091T1 (el)
CZ (1) CZ2002842A3 (el)
DE (2) DE60040879D1 (el)
DK (1) DK1210112T3 (el)
ES (2) ES2261237T3 (el)
GB (1) GB9921147D0 (el)
GC (1) GC0000202A (el)
HK (1) HK1048436B (el)
HU (1) HUP0202826A3 (el)
IL (1) IL148455A0 (el)
MX (1) MXPA02002483A (el)
MY (1) MY134860A (el)
NO (1) NO20021115L (el)
NZ (1) NZ517622A (el)
PL (1) PL353923A1 (el)
PT (1) PT1210112E (el)
TR (1) TR200200608T2 (el)
WO (1) WO2001017550A2 (el)
ZA (1) ZA200201834B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
BR0315810A (pt) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
KR100525321B1 (ko) * 2002-12-13 2005-11-02 안웅식 파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
AU2005253723B2 (en) * 2004-06-16 2011-01-20 Glaxosmithkline Biologicals S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
MX2007011756A (es) * 2005-03-23 2008-03-11 Glaxosmithkline Biolog Sa Uso de un virus de la gripe y un adyuvante de emulsion de aceite en agua para inducir la respuesta mejorada de la celulas b de memoria y/o celulas t cd4.
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL1968630T3 (pl) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multiwalentne immunogenne kompozycje PCV2
EP2374475A1 (en) 2005-12-29 2011-10-12 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
BRPI0915076A2 (pt) * 2008-06-09 2017-03-14 Bharat Biotech Int Ltd composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas.
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
PL2846829T3 (pl) * 2012-05-09 2022-01-24 Bharat Biotech International Limited Kombinacje szczepionkowe
KR101347288B1 (ko) * 2012-05-18 2014-01-06 안웅식 융합 폴리펩타이드 ｈｐｖ 항원을 이용한 ｈｐｖ 항체 스크리닝 키트

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563091A1 (en) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
AU685443B2 (en) * 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
ATE441432T1 (de) * 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
CN1299288A (zh) * 1998-03-09 2001-06-13 史密丝克莱恩比彻姆生物有限公司 联合疫苗组合物
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
ES2261237T3 (es) 2006-11-16
DE60027440D1 (de) 2006-05-24
PT1210112E (pt) 2006-08-31
EP1731167A1 (en) 2006-12-13
US20080118527A1 (en) 2008-05-22
GB9921147D0 (en) 1999-11-10
ATE323509T1 (de) 2006-05-15
KR20020027629A (ko) 2002-04-13
CZ2002842A3 (cs) 2002-08-14
WO2001017550A2 (en) 2001-03-15
TR200200608T2 (tr) 2002-08-21
BR0014172A (pt) 2002-05-14
JP4694745B2 (ja) 2011-06-08
GC0000202A (en) 2006-03-29
HUP0202826A2 (hu) 2002-12-28
HK1048436B (zh) 2006-10-27
ATE414533T1 (de) 2008-12-15
EP1210112B1 (en) 2006-04-19
ES2314816T3 (es) 2009-03-16
AR025503A1 (es) 2002-11-27
AU7284800A (en) 2001-04-10
AU765245B2 (en) 2003-09-11
HK1048436A1 (en) 2003-04-04
PL353923A1 (en) 2003-12-15
NO20021115D0 (no) 2002-03-06
US20050123562A1 (en) 2005-06-09
CN1171637C (zh) 2004-10-20
JP2003508494A (ja) 2003-03-04
WO2001017550A3 (en) 2001-11-29
US7371390B2 (en) 2008-05-13
EP1210112A2 (en) 2002-06-05
NZ517622A (en) 2003-09-26
DE60040879D1 (de) 2009-01-02
DE60027440T2 (de) 2006-10-19
MY134860A (en) 2007-12-31
KR100782637B1 (ko) 2007-12-06
HUP0202826A3 (en) 2008-04-28
CN1390136A (zh) 2003-01-08
CA2381047A1 (en) 2001-03-15
ZA200201834B (en) 2004-04-28
DK1210112T3 (da) 2006-08-14
NO20021115L (no) 2002-04-30
EP1731167B1 (en) 2008-11-19
IL148455A0 (en) 2002-09-12
CA2381047C (en) 2010-08-03
MXPA02002483A (es) 2002-08-28

Similar Documents

Publication Publication Date Title
CY1106091T1 (el) Εμβολιο εναντι hbv και hpv
CY1106090T1 (el) Νεα συνθεση
MY135965A (en) Vaccine against hepatitis b and herpes simplex virus
ES2070997T3 (es) Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
DE69839359D1 (de) Verfahren und Reagenzien zur Erzeugung einer CD8+T-Zellen Immunantwort gegen Hepatitis B oder C
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
ATE287728T1 (de) Adjuvierte rekombinante lebendimpfstoffe gegen influenza- oder herpesviren
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
ATE254474T1 (de) Impfstoffzusammensetzung gegen herpes simplex virus und methoden zur verwendung
KR930703435A (ko) 단순 포진 비루스-1 결실 변종 및 그의 백신
MY134041A (en) Novel composition
BR9704879A (pt) Composição de vacina e uso de um vírus cav vivo
DE69922804D1 (de) Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien
BRPI0017420B8 (pt) composição de vacina, hpv 16 l1 e hpv 18 l1 vpl
AR016987A1 (es) Composiciones acuosas de vacuna acuosaa para la profilaxis de hepatitis b o hepatitis b/a
DE69433760D1 (de) Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält
Esterhuysen The antigenic variation of foot-and-mouth disease viruses and its significance in the epidemiology of the disease in southern Africa.
PT100460A (pt) Partiiculas derivadas de virus de herpes e vacinas que as contem
DE69130953D1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie